• Home Selective-spectrum.


Affinium announces AFN-1252 Phase I study outcomes in staphylococcal infections Today the results of a fresh multiple ascending dose Phase I study of it is novel Affinium Pharmaceuticals announced, selective-spectrum, anti-staphylococcal agent, AFN-1252 in a novel oral formulation. The scholarly study examined the tolerability, pharmacokinetics and protection of immediate launch tablets of AFN-1252. Cohorts of healthful volunteers were dosed 200mg, 300mg, and 400 mg of AFN-1252 once for 10 times daily electile dysfunction . The pharmacokinetic outcomes indicate that dosages of either 300 mg, and 400mg, once daily or 200 mg twice daily, met or exceeded exposures necessary for the treatment of serious staphylococcal infections.